Geopolitics Alpha

Market closed · last trade · ETFs, Alpaca IEX

Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus

Published . Updated .

Key takeaways

  • Conference spotlight on Vertex Pharmaceuticals and a busy late stage pipeline Vertex Pharmaceuticals (VRTX) heads into back to back London conference appearances as investors watch for commentary on a November 30 U.S.
  • Exposed: XLV, XBI, JNJ, VRTX, PFE
  • Market reaction: price tracking starts with the next trading session.

Market Call

Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.

Get these market calls by email

The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.

Free. We only use your email to send the digest and never sell or share it. See our privacy policy.

Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus

Conference spotlight on Vertex Pharmaceuticals and a busy late stage pipeline Vertex Pharmaceuticals (VRTX) heads into back to back London conference appearances as investors watch for commentary on a November 30 U.S. regulatory decision for kidney drug povetacicept and a

Directly affected

  • VRTX Vertex Pharmaceuticals Inc / Ma+3.8% 30d

    Named in this report.

Indirectly affected

  • XLV Health Care Select Sector SPDR

    Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.

  • XBI SPDR S&P Biotech ETF

    SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.

  • EWU iShares MSCI United Kingdom ETF+0.6% 10d

    iShares MSCI United Kingdom ETF holds stocks listed in the UK, which this story is about (“london”).

  • LLY Eli Lilly and+25.1% 30d

    Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.

  • JNJ Johnson & Johnson+12.1% 30d

    Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.

  • PFE Pfizer+5.2% 30d

    Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.

  • MRK Merck+3.5% 30d

    Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.

Price reaction, T-5 to T+3

TickerT-5T-3T-1T0T+1T+2T+3
VRTX+2.45%+0.84%baseafter closeafter closeafter closeafter close
XLV+2.00%+1.95%baseafter closeafter closeafter closeafter close
XBI+7.54%+3.62%baseafter closeafter closeafter closeafter close
EWUNo price data for this ticker———————
LLY+1.56%+2.06%baseafter closeafter closeafter closeafter close
JNJ+0.58%+2.60%baseafter closeafter closeafter closeafter close
PFE+3.48%+1.55%baseafter closeafter closeafter closeafter close
MRK+2.66%+3.05%baseafter closeafter closeafter closeafter close

Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.

Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus Yahoo Finance

Source: Yahoo Finance

Earlier energy stories for Select Sector Spdr Tr (XLV): 3 cases

Select Sector Spdr Tr (XLV) the next day, across 3 earlier stories: average -1.92%, largest gain -1.92%, largest drop -1.92%, from 3 prices.

CompanyWhenAverageLargest gainLargest dropPrices
Select Sector Spdr Tr (XLV)the next day-1.92%-1.92%-1.92%3
Spdr Series Trust (XBI)the next day-3.49%-3.49%-3.49%1
Johnson & Johnson (JNJ)the next day-2.54%-2.54%-2.54%2

How far Select Sector Spdr Tr (XLV) has moved since 18 Nov 2026

CompanyWhenMoveStatus
Johnson & Johnson (JNJ)three days earlier+2.60%final price
Johnson & Johnson (JNJ)five days earlier+0.58%final price
Eli Lilly (LLY)three days earlier+2.06%final price
Eli Lilly (LLY)five days earlier+1.56%final price
MRKthree days earlier+3.05%final price
MRKfive days earlier+2.66%final price
Pfizer (PFE)three days earlier+1.55%final price
Pfizer (PFE)five days earlier+3.48%final price
Vertex Pharmaceuticals Inc / Ma (VRTX)three days earlier+0.84%final price
Vertex Pharmaceuticals Inc / Ma (VRTX)five days earlier+2.45%final price
Spdr Series Trust (XBI)three days earlier+3.62%final price
Spdr Series Trust (XBI)five days earlier+7.54%final price
Select Sector Spdr Tr (XLV)three days earlier+1.95%final price
Select Sector Spdr Tr (XLV)five days earlier+2.00%final price

Trades by members of Congress and officials in the stocks in this story

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Companies in energy around Select Sector Spdr Tr (XLV)

Companies carried with this story

  • XLV Select Sector Spdr Tr

    In “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence. Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story

  • XBI Spdr Series Trust

    For “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story

  • JNJ Johnson & Johnson

    Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence in the 18 Nov 2026 story “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus.” Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story

  • VRTX Vertex Pharmaceuticals Inc / Ma

    For “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Vertex Pharmaceuticals Inc / Ma (VRTX) is linked, with no stored direction, medium confidence. Reason on file: Vertex Pharmaceuticals (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story

  • PFE Pfizer

    In “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story

  • LLY Eli Lilly

    In “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story

How energy news reaches Select Sector Spdr Tr (XLV)

On 18 Nov 2026, “Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus” is the story that connects Select Sector Spdr Tr (XLV) to Energy.

What ties Select Sector Spdr Tr (XLV) to the headline is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story

Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story

Dates and price levels for Select Sector Spdr Tr (XLV)

JNJ traded between 251.53 and 286.04 across 20 sessions. The latest close on file is 283.56.

The energy score for Select Sector Spdr Tr (XLV)

46 out of 100

“Vertex Pharmaceuticals (VRTX) Could Be 11% Undervalued On Late Stage Pipeline Focus” scores 46 out of 100. The score uses 1 source, and 6 linked companies.